Progesterone Hypersensitivity Induced by Exogenous Progesterone Exposure.

Progesterone hypersensitivity (PH) is a rare hypersensitivity reaction to either endogenous or exogenous progesterone. There are around 200 reported cases of progesterone hypersensitivity in the medical literature. We present the case of a 31-year-old female who presented with cyclical urticaria and angioedema after exogenous progesterone exposure. Her symptoms would begin a few days before her menstrual cycle began and resolve after menstruation. She only had partial recovery of her symptoms with antihistamines, steroids, montelukast, and omalizumab. She needed treatment with oral contraceptives and had a resolution of symptoms, but subsequently developed a recurrence again. Given the rarity of this condition, the diagnosis is often delayed. This diagnosis should be considered for women of reproductive age who present with cyclic hypersensitivity or allergic symptoms.

Outcomes of Acute Mesenteric Ischemia in Patients With COVID-19: A Nationwide Database Study.

Introduction Initially regarded as primarily a respiratory illness, coronavirus disease 2019 (COVID-19) has since been recognized as a complex disease affecting multiple systems. A COVID-19 infection can cause a hypercoagulable state leading to thrombotic complications in various systems. Acute mesenteric ischemia (AMI) has been reported as a rare complication of COVID-19, carrying a significant mortality rate. Although some risk factors for AMI in COVID-19 patients have been identified, there is a lack of large-scale studies examining outcomes and predictors of mortality. This study aims to assess the outcomes and identify predictors of mortality in a larger cohort of hospitalized COVID-19 patients with AMI, utilizing a retrospective analysis of the National Inpatient Sample (NIS) database. Methods Data from the 2020 NIS database were retrospectively analyzed. Patients aged 18 years and older, with a principal diagnosis of mesenteric ischemia were identified using the International Classification of Diseases, Tenth Revision (ICD-10) codes. The population was divided into mesenteric ischemia with COVID-19 and mesenteric ischemia without COVID-19. Patient demographics, comorbidities, hospital characteristics, and outcomes such as mortality, length of stay, and costs were analyzed. Multivariable logistic regression was performed to identify predictors of mortality. Results Among the 18,185 patients with acute mesenteric ischemia in 2020, 2.1% (n=370) had AMI with COVID-19 while 97.9% (n=17,810) had AMI only. In comparison to those without COVID-19, patients with AMI and COVID-19 had significantly higher in-hospital mortality. They also had higher odds of acute kidney injury, coronary artery disease, and ICU admission. Increasing age and white race were identified as predictors of mortality. Patients with COVID-19 had longer hospital stays and higher total costs compared to those without COVID-19. Discussion In this retrospective analysis of the NIS database, COVID-19 infection was associated with higher mortality in patients with AMI. Additionally, COVID-19 patients with AMI experienced increased odds of complications and higher resource utilization. Advanced age and white race were identified as predictors of mortality. These findings emphasize the importance of early recognition and management of AMI in COVID-19 patients, especially in high-risk populations.

Osteoporosis in a 60-Year-Old Male With a History of Chronic Myeloid Leukemia Treated With Imatinib Mesylate.

Secondary osteoporosis is defined as a decline in bone mineral density due to any underlying etiology, which usually results in accelerated bone loss than expected for the individual's age or gender. Almost 50-80% of men diagnosed with osteoporosis have secondary osteoporosis. We present a case of a 60-year-old male with secondary osteoporosis with a history of imatinib mesylate-treated chronic myeloid leukemia (CML). Imatinib mesylate has revolutionized the management of individuals with chronic myeloid leukemia, which is now managed as a chronic disease. Imatinib has been demonstrated to cause dysregulation of bone metabolism. The long-term effects of imatinib on bone metabolism are still unknown.

Thyrotoxic Periodic Paralysis With Severe Hypokalemia Precipitated by Acute Alcohol Intoxication in a Patient With Graves' Disease.

We present a case of a 29-year-old male who presented with thyrotoxic periodic paralysis (TPP) precipitated by acute alcohol intoxication. TPP is an endocrine emergency that presents with an episode of acute flaccid paralysis with hypokalemia in the setting of thyrotoxicosis. Individuals who present with TPP are thought to have an underlying genetic predisposition. Overactivation of the Na+/K+ ATPase channel leads to large-scale intracellular shifts in potassium, leading to low serum levels and the clinical manifestations of TPP. Severe hypokalemia can lead to life-threatening complications such as ventricular arrhythmias and respiratory failure. Therefore, timely recognition and management are essential in cases of TPP. In addition, understanding the precipitating factors is necessary for adequate counseling of these patients to prevent further episodes.

Guillain-Barre Syndrome Secondary to the Use of Dabrafenib and Trametinib for the Treatment of Advanced Thyroid Carcinoma.

BRAF V600E mutation in thyroid malignancies is associated with an aggressive phenotype with more rapid tumor growth and higher mortality. V600E is a driver mutation in the BRAF proto-oncogene, where valine (V) is substituted by glutamic acid (E) at amino acid 600. New chemotherapeutic agents targeting the mitogen-activated protein kinase (MAPK) pathway, including direct BRAF inhibitors, have become available and are increasingly used in various advanced thyroid malignancies. These agents are associated with various rare neurological adverse effects. We present a case of Guillain-Barre syndrome (GBS) secondary to dabrafenib and trametinib therapy for the management of anaplastic thyroid carcinoma. A few cases of GBS have been reported previously with the use of these agents in the treatment of melanoma. To our knowledge, this is the first case of GBS with the use of dabrafenib and trametinib for advanced thyroid malignancy. The knowledge of this rare, potentially life-threatening condition is important for clinicians to know, given the increased use of these agents in managing advanced thyroid malignancies.